AKT1 and urinary bladder cancer: Therefore, although PIK3CA is a valuable therapeutic target for inhibitors of PI3K/AKT/mTOR pathways in advanced bladder cancer (Ross et al., 2016; Willis et al., 2020), the detailed expression status of the mutations should be carefully evaluated when the targeted therapy is considered.